Recent progress in antiretrovirals - lessons from resistance

被引：35

作者：

Adamson, Catherine S. ^{[1
]}

Freed, Eric O. ^{[1
]}

机构：

[1] NCI, Virus Cell Interact Sect, HIV Drug Resistance Program, Frederick, MD 21702 USA

来源：

DRUG DISCOVERY TODAY | 2008年 / 13卷 / 9-10期

关键词：

D O I：

10.1016/j.drudis.2008.02.003

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Recent failures in efforts to develop an effective vaccine against HIV-1 infection have emphasized the importance of antiretroviral therapy in treating HIV-1-infected patients. Thus far, inhibitors of two viral enzymes, reverse transcriptase and protease, have had a profoundly positive impact on the survival of HIV-1-infected patients. However, new inhibitors that act at diverse steps in the viral replication cycle are urgently needed because of the development of resistance to currently available antiretrovirals. This review summarizes recent progress in antiretroviral drug discovery and development by specifically focusing on novel inhibitors of three phases of replication: viral entry, integration of the viral DNA into the host cell genome and virus particle maturation.

引用

页码：424 / 432

页数：9

共 94 条

[11] Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients [J].

DeJesus, Edwin ;

Berger, Daniel ;

Markowitz, Martin ;

Cohen, Calvin ;

Hawkins, Trevor ;

Ruane, Peter ;

Elion, Richard ;

Farthing, Charles ;

Zhong, Lijie ;

Cheng, Andrew K. ;

McColl, Dainian ;

Kearney, Brian P. .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (01) :1-5

[12] MINIMAL REQUIREMENTS FOR THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 V3 DOMAIN TO SUPPORT THE SYNCYTIUM-INDUCING PHENOTYPE - ANALYSIS BY SINGLE AMINO-ACID SUBSTITUTION [J].

DEJONG, JJ ;

DERONDE, A ;

KEULEN, W ;

TERSMETTE, M ;

GOUDSMIT, J .

JOURNAL OF VIROLOGY, 1992, 66 (11) :6777-6780

[13] Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity [J].

Dorr, P ;

Westby, M ;

Dobbs, S ;

Griffin, P ;

Irvine, B ;

Macartney, M ;

Mori, J ;

Rickett, G ;

Smith-Burchnell, C ;

Napier, C ;

Webster, R ;

Armour, D ;

Price, D ;

Stammen, B ;

Wood, A ;

Perros, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4721-4732

[14] HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase [J].

Espeseth, AS ;

Felock, P ;

Wolfe, A ;

Witmer, M ;

Grobler, J ;

Anthony, N ;

Egbertson, M ;

Melamed, JY ;

Young, S ;

Hamill, T ;

Cole, JL ;

Hazuda, DJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (21) :11244-11249

[15]

Esté JA, 1999, J VIROL, V73, P5577

[16] HIV entry inhibitors [J].

Este, Jose A. ;

Telenti, Amalio .

LANCET, 2007, 370 (9581) :81-88

[17] Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360 [J].

Fikkert, V ;

Hombrouck, A ;

Van Remoortel, B ;

De Maeyer, M ;

Pannecouque, C ;

De Clercq, E ;

Debyser, Z ;

Witvrouw, M .

AIDS, 2004, 18 (15) :2019-2028

[18] Development of resistance against Diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations [J].

Fikkert, V ;

Van Maele, B ;

Vercammen, J ;

Hantson, A ;

Van Remoortel, B ;

Michiels, M ;

Gurnari, C ;

Pannecouque, C ;

De Maeyer, M ;

Engelborghs, Y ;

De Clercq, E ;

Debyser, Z ;

Witvrouw, M .

JOURNAL OF VIROLOGY, 2003, 77 (21) :11459-11470

[19]

Finnegan C., 2006, Infectious Disorders - Drug Targets, V6, P355, DOI 10.2174/187152606779025851

[20]

Freed E.O., 2007, Fields Virology, P2107

← 1 2 3 4 5 6 7 8 9 10 →